Protagenic Therapeutics Inc
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Stock Performance Snapshot
Financial Health
Protagenic Therapeutics is showing positive cash flow and reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PTIX
Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Microcap, high risk
With a market cap near $6M, the stock can be very volatile and thinly traded — potential gains come with a higher risk of loss and limited liquidity.
Binary catalyst profile
Value may hinge on clinical, regulatory or financing events that can move the share price sharply in either direction; outcomes are uncertain.
Due diligence essentials
Review filings, cash runway and management track record; small biotechs often need further funding and carry execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
